Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / KHTRF - Incyte and Knight Therapeutics ink exclusive supply and distribution agreement

KHTRF - Incyte and Knight Therapeutics ink exclusive supply and distribution agreement

Knight Therapeutics Inc
Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), and Knight Therapeutics (OTC:KHTRF) have entered into an agreement for the exclusive rights to distribute tafasitamab (Monjuvi) and pemigatinib (Pemazyre) in Latin America. Under the terms of the agreement, Incyte will be responsible for the development, manufacture and supply, while Knight will be responsible for seeking the necessary regulatory approvals and distributing both medicines in Latin America. Tafasitamab in combination with lenalidomide is approved in the U.S. and Europe for the treatment of certain adult patients with lymphoma. Pemigatinib is approved in the U.S., Europe and Japan for the treatment of certain adult patients with cholangiocarcinoma.

For further details see:

Incyte and Knight Therapeutics ink exclusive supply and distribution agreement
Stock Information
Company Name: Knight Therapeutics Inc
Stock Symbol: KHTRF
Market: OTC
Website: gud-knight.com
Menu
KHTRF KHTRF Quote KHTRF Short KHTRF News KHTRF Articles KHTRF Message Board
Get KHTRF Alerts

News, Short Squeeze, Breakout and More Instantly...